PATENT CLAIM ANALYSIS

Application Number: 15890040
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "183000"]

Abstract:
The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

Claim (Index 13):
The compound according to  claim 2  wherein L is a linker group according to the chemical formula: Where Z and Z\u2032 are each independently a bond, \u2014(CH 2 ) i \u2014O, \u2014(CH 2 ) i \u2014S, \u2014(CH 2 ) i \u2014N\u2014R, wherein said \u2014(CH 2 ) i  group, if present in Z or Z\u2032, is bonded to a connector (CT), an alternative linker, A B M and/or UPAR B M; Each R is H, or a C 1 -C 3  alkyl or alkanol group; Each R 2  is independently H or a C 1 -C 3  alkyl group; Each Y is independently a bond, O, S or N\u2014R; Each i is independently 0 to 100, 0 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 0, 1, 2, 3, 4 or 5; D is \u2003or a bond, with the proviso that Z, Z\u2032 and D are not each simultaneously bonds; j is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5; m\u2032 is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5; n is 1 to 100, 1 to 75, 1 to 60, to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5 (n is preferably 2); X 1  is O, S or N\u2014R; and R is as described above, or a pharmaceutical salt thereof.

Metadata:
- Claim Count in Document: 104.0
- Percentile: 88.0
- Lexical Diversity: 1.93976
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14397995', '15374272', '13173480', '14480204', '12991926']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8115018294042337
- 35 USC 102 Novelty (BERT): 0.5222036974640579
- Combined Prediction Score: 0.7825720162102161
- Mean Citation Score: 313.007338
- Max Citation Score: 320.29672
- Similarity Product: 222.618169182868

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test